Company / PP&E (Net)
VYNE Therapeutics Inc. PP&E (Net) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$113.0K
FY2025
5-year range
$113.0K / $354.0K
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $354,000 to $113,000 over the past 4 years.
Based on SEC 10-K filings.
$113,000 in FY2025 with a 5-year CAGR of -27.3%.
Declined from $354,000 to $113,000 over the past 4 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -27.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -27.3%, indicating a declining trend.
- In FY2025, pp&e (net) increased 0.0% year-over-year.
- Peak pp&e (net) was recorded in FY2020.
- Lowest pp&e (net) in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $113.0K | +0.0% |
| FY2024 | $113.0K | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $354.0K | -36.2% |
| FY2020 | $555.0K | +466.3% |
| FY2019 | $98.0K | -32.9% |
| FY2018 | $146.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026